These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 22153942)
41. Sulfonamides with the N-alkyl-N'-dialkylguanidine moiety as 5-HT7 receptor ligands. Zajdel P; Subra G; Verdie P; Gabzdyl E; Bojarski AJ; Duszyńska B; Martinez J; Pawłowski M Bioorg Med Chem Lett; 2009 Aug; 19(16):4827-31. PubMed ID: 19560916 [TBL] [Abstract][Full Text] [Related]
42. Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel? Miller KJ; Wacker DA Future Med Chem; 2010 Dec; 2(12):1761-75. PubMed ID: 21428799 [TBL] [Abstract][Full Text] [Related]
43. Synthesis, biological activity, and molecular modeling of selective 5-HT(2C/2B) receptor antagonists. Forbes IT; Dabbs S; Duckworth DM; Ham P; Jones GE; King FD; Saunders DV; Blaney FE; Naylor CB; Baxter GS; Blackburn TP; Kennett GA; Wood MD J Med Chem; 1996 Dec; 39(25):4966-77. PubMed ID: 8960557 [TBL] [Abstract][Full Text] [Related]
44. Roles of 5-hydroxytryptamine (5-HT) receptor subtypes in the inhibitory effects of 5-HT on C-fiber responses of spinal wide dynamic range neurons in rats. Liu FY; Xing GG; Qu XX; Xu IS; Han JS; Wan Y J Pharmacol Exp Ther; 2007 Jun; 321(3):1046-53. PubMed ID: 17329553 [TBL] [Abstract][Full Text] [Related]
45. Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists. Galeazzi R; Massaccesi L; Piva F; Principato G; Laudadio E J Mol Model; 2014 Mar; 20(3):2120. PubMed ID: 24562856 [TBL] [Abstract][Full Text] [Related]
46. The structure of human serotonin 2c G-protein-coupled receptor bound to agonists and antagonists. Bray JK; Goddard WA J Mol Graph Model; 2008 Aug; 27(1):66-81. PubMed ID: 18499489 [TBL] [Abstract][Full Text] [Related]
47. Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation. Canal CE; Cordova-Sintjago TC; Villa NY; Fang LJ; Booth RG Eur J Pharmacol; 2011 Dec; 673(1-3):1-12. PubMed ID: 22020288 [TBL] [Abstract][Full Text] [Related]
48. Peptide inhibitors disrupt the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog to allosterically modulate cellular signaling and behavior. Anastasio NC; Gilbertson SR; Bubar MJ; Agarkov A; Stutz SJ; Jeng Y; Bremer NM; Smith TD; Fox RG; Swinford SE; Seitz PK; Charendoff MN; Craft JW; Laezza FM; Watson CS; Briggs JM; Cunningham KA J Neurosci; 2013 Jan; 33(4):1615-30. PubMed ID: 23345234 [TBL] [Abstract][Full Text] [Related]
50. Quinolinesulfonamides of aryloxy-/arylthio-ethyl piperidines: influence of an arylether fragment on 5-HT1A/5-HT7 receptor selectivity. Grychowska K; Marciniec K; Canale V; Szymiec M; Glanowski G; Satała G; Maślankiewicz A; Pawłowski M; Bojarski AJ; Zajdel P Arch Pharm (Weinheim); 2013 Mar; 346(3):180-8. PubMed ID: 23381952 [TBL] [Abstract][Full Text] [Related]
51. Design of novel multiple-acting ligands towards SERT and 5-HT2C receptors. Eliás O; Agai-Csongor E; Domány G; Keserű GM; Gere A; Kiss B; Hellinger E; Vastag M; Gyertyán I Bioorg Med Chem Lett; 2014 May; 24(9):2118-22. PubMed ID: 24717153 [TBL] [Abstract][Full Text] [Related]
52. Selective 5-HT2C receptor agonists: Design and synthesis of pyridazine-fused azepines. Green MP; McMurray G; Storer RI Bioorg Med Chem Lett; 2016 Aug; 26(16):4117-21. PubMed ID: 27381086 [TBL] [Abstract][Full Text] [Related]
54. We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders. Cheng J; Kozikowski AP ChemMedChem; 2015 Dec; 10(12):1963-7. PubMed ID: 26507582 [TBL] [Abstract][Full Text] [Related]
55. Insights into binding modes of 5-HT2c receptor antagonists with ligand-based and receptor-based methods. Lu C; Jin F; Li C; Li W; Liu G; Tang Y J Mol Model; 2011 Oct; 17(10):2513-23. PubMed ID: 21203788 [TBL] [Abstract][Full Text] [Related]
56. Synthesis and Biological Evaluation of Disubstituted Pyrimidines as Selective 5-HT Kim J; Kim YJ; Londhe AM; Pae AN; Choo H; Kim HJ; Min SJ Molecules; 2019 Sep; 24(18):. PubMed ID: 31491978 [TBL] [Abstract][Full Text] [Related]
57. 5-HT2 receptor affinity, docking studies and pharmacological evaluation of a series of 1,3-disubstituted thiourea derivatives. Bielenica A; Kędzierska E; Koliński M; Kmiecik S; Koliński A; Fiorino F; Severino B; Magli E; Corvino A; Rossi I; Massarelli P; Kozioł AE; Sawczenko A; Struga M Eur J Med Chem; 2016 Jun; 116():173-186. PubMed ID: 27061981 [TBL] [Abstract][Full Text] [Related]
58. Structural insight into receptor-selectivity for lurasidone. Ichikawa O; Okazaki K; Nakahira H; Maruyama M; Nagata R; Tokuda K; Horisawa T; Yamazaki K Neurochem Int; 2012 Dec; 61(7):1133-43. PubMed ID: 22929996 [TBL] [Abstract][Full Text] [Related]
59. Exploration of synthetic approaches and pharmacological evaluation of PNU-69176E and its stereoisomer as 5-HT2C receptor allosteric modulators. Ding C; Bremer NM; Smith TD; Seitz PK; Anastasio NC; Cunningham KA; Zhou J ACS Chem Neurosci; 2012 Jul; 3(7):538-45. PubMed ID: 22860223 [TBL] [Abstract][Full Text] [Related]